Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5627813 | 0.91 | PTGER1 (0.46) | FFAR4FFAR1MAOBMAOAKMT2A | |
| SCHEMBL5474984 | 0.90 | CCR5 (0.53) | MAOBMAOALRRK2 | |
| SCHEMBL5627449 | 0.90 | LRRK2 (0.53) | FFAR4FFAR1MAOBMAOAKMT2A | |
| SCHEMBL6185410 | 0.89 | MAOB (0.58) | FFAR4FFAR1MAOBMAOAKMT2A | |
| SCHEMBL5628371 | 0.88 | LRRK2 (0.58) | MAOBKMT2AMEN1LRRK2 | |
| SCHEMBL5631480 | 0.88 | KMT2A (0.56) | MAOBMAOAKMT2AMEN1RAB9A | |
| SCHEMBL5628010 | 0.84 | MAOB (0.52) | MAOBKMT2AMEN1ALDH1A1 | |
| SCHEMBL6190736 | 0.83 | MAOB (0.54) | FFAR4FFAR1MAOBMAOAKMT2A | |
| SCHEMBL6188332 | 0.82 | MAOB (0.53) | FFAR4FFAR1MAOBMAOAKMT2A | |
| SCHEMBL5627323 | 0.77 | SGMS2 (0.55) | KMT2AMEN1LMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | FFAR4 1238/4885FFAR1 730/4885MAOB 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.